-
CardioGenesis (Foothill Ranch, California) reported that Chairman and Chief Executive Officer Michael Quinn has resumed the position of president, replacing Darrell Eckstein, who left the company to pursue other interests.
-
Abbott Laboratories (Abbott Park, Illinois) unveiled a collaboration and license agreement with global pharmaceutical company Wyeth (Madison, New Jersey) to develop an automated blood test to monitor therapeutic levels of the anti-rejection drug Rapamune.
-
One of the real buzzes at Novembers annual scientific sessions of the American Heart Association (AHA; Dallas, Texas) was the continuing clinical validation of the role of public access defibrillation in reducing mortality. Clinical studies showing the effectiveness of automated external defibrillators (AEDs) presented at the AHA conference were excellent news for virtually every major defibrillator company.
-
-
-
TFD as a single measurement carries significant prognostic importance in women with comprehensively staged endometrial cancer.
-
Most Americans believe that screening tests for cancer save lives and that it is irresponsible not to undergo recommended periodic screening. The presence of a large market for cancer screening may make Americans vulnerable to unproven and unnecessary testing.
-
In a series of chronic-phase CML patients who had previously been treated with interferon and who subsequently received imatinib mesylate, the appearance of myelosuppression (Grade > 3 neutropenia or thrombocytopenia) was associated with significantly less frequent major or complete cytogenetic responses.
-
Based on its improved safety profile, capecitabine has the potential to replace 5-FU/LV as standard adjuvant treatment for patients with colon cancer.
-
In a series from Korea, treatment outcomes for older (age older than 60 years) patients with diffuse large-cell lymphoma were analyzed with particular focus on dose intensity of doxorubicin. Although, overall, older patients did not achieve the same level of complete response, for those who were able to maintain doxorubicin dose intensity, response rates were comparable to younger patients.
